by 
The Polycyticc Ovary Syndrome (PCOS) Treatment Market is estimated to be valued at US$ 1,086.6 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
PCOS is a hormonal disorder common among women of reproductive age. It is characterized by enlarged ovaries with small cysts on the outer edges. Symptoms include irregular or absent menstrual periods, excess androgen and masculinization, acne, obesity, and infertility. Currently available treatment options aim to induce menstruation, manage symptoms and improve chances of conception. Drugs such as oral contraceptives, insulin sensitizers and anti-androgens are used to treat PCOS.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/polycystic-ovarian-syndrome-treatment-market-1589
Market Dynamics:
Increasing prevalence of obesity and diabetes mellitus have emerged as major drivers for the PCOS treatment market. Sedentary lifestyles adopted by the urban population have led to a rise in weight gain and insulin resistance, leading to PCOS. According to the 2018 NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) report, more than 1 in 10 women of reproductive age in the U.S. has PCOS. The lack of awareness about self-care and healthy lifestyle also contributes to the increased incidence of PCOS. Additionally, growing awareness regarding available PCOS treatment options and management is further expected to propel the market growth over the forecast period.
Segment Analysis
The polycystic ovary syndrome (PCOS) treatment market is segmented into insulin sensitizing agents, oral contraceptives, antiandrogens and others. Among these, the insulin sensitizing agent segment dominates the market and accounts for over 30% market share owing to rising number of patients suffering from insulin resistance and high blood sugar levels. Moreover, medicines like metformin help reduce weight and other symptoms that aid in better management of PCOS.
PEST Analysis
Political: Government policies supporting awareness and treatment of PCOS positively impact market growth.
Economic: Rising healthcare spending and increasing incomes in emerging nations boost market value.
Social: Growing PCOS awareness via social media, patient communities and physician initiatives expands the patient pool.
Technological: Developments in personalized treatment approaches and combination drug therapies widen therapeutic options.
Key Takeaways
The global polycystic ovary syndrome (PCOS) treatment market is expected to witness high growth, exhibiting CAGR of 4.8% over the forecast period, due to increasing awareness about PCOS and availability of treatment options.
The North America region accounts for the largest share in the global PCOS treatment market owing to advanced healthcare infrastructure, high healthcare spending and growing diagnosis rates in the US and Canada. The Asia Pacific region is projected to witness the fastest growth during the forecast period, driven by rising incidence of PCOS cases, improving access to healthcare facilities and increasing focus of key players on expanding in developing Asian countries.
Key players operating in the PCOS treatment market are Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., Evotec SE, McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG. Major players are engaged in new product development and collaborations to strengthen their presence in the highly consolidated PCOS treatment market.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
